OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 1,500,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPKGet Free Report) CEO Phillip Md Et Al Frost bought 1,500,000 shares of OPKO Health stock in a transaction on Wednesday, February 7th. The stock was acquired at an average cost of $0.98 per share, for a total transaction of $1,470,000.00. Following the acquisition, the chief executive officer now owns 207,368,225 shares in the company, valued at approximately $203,220,860.50. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, January 18th, Phillip Md Et Al Frost acquired 400,000 shares of OPKO Health stock. The shares were purchased at an average cost of $0.97 per share, for a total transaction of $388,000.00.
  • On Tuesday, January 16th, Phillip Md Et Al Frost acquired 1,000,000 shares of OPKO Health stock. The shares were purchased at an average cost of $0.95 per share, for a total transaction of $950,000.00.
  • On Thursday, January 11th, Phillip Md Et Al Frost acquired 511,531 shares of OPKO Health stock. The shares were purchased at an average cost of $0.94 per share, for a total transaction of $480,839.14.
  • On Friday, January 5th, Phillip Md Et Al Frost bought 1,500,000 shares of OPKO Health stock. The shares were bought at an average cost of $0.90 per share, for a total transaction of $1,350,000.00.
  • On Thursday, November 9th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.28 per share, with a total value of $640,000.00.

OPKO Health Trading Up 2.3 %

Shares of OPK stock opened at $1.00 on Thursday. The company’s fifty day simple moving average is $1.28 and its two-hundred day simple moving average is $1.47. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.78 and a quick ratio of 1.44. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $2.24. The stock has a market capitalization of $773.06 million, a price-to-earnings ratio of -3.70 and a beta of 1.78.

OPKO Health (NASDAQ:OPKGet Free Report) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $178.60 million during the quarter, compared to the consensus estimate of $174.78 million. OPKO Health had a negative return on equity of 13.63% and a negative net margin of 23.94%. The company’s revenue for the quarter was down .6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) EPS. As a group, analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in OPK. Oak Thistle LLC purchased a new stake in OPKO Health during the second quarter valued at about $36,000. Citigroup Inc. boosted its position in OPKO Health by 7.8% during the second quarter. Citigroup Inc. now owns 1,616,343 shares of the biotechnology company’s stock valued at $3,507,000 after buying an additional 117,396 shares during the period. Bank of New York Mellon Corp boosted its position in OPKO Health by 3.0% during the second quarter. Bank of New York Mellon Corp now owns 1,588,262 shares of the biotechnology company’s stock valued at $3,447,000 after buying an additional 46,219 shares during the period. Raymond James & Associates boosted its position in OPKO Health by 19.5% during the second quarter. Raymond James & Associates now owns 49,346 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 8,051 shares during the period. Finally, SG Americas Securities LLC boosted its position in OPKO Health by 164.1% during the third quarter. SG Americas Securities LLC now owns 204,835 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 127,275 shares during the period. Institutional investors own 22.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th.

View Our Latest Research Report on OPKO Health

About OPKO Health

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Featured Articles

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.